Aldeyra Therapeutics Sees Unusually High Options Volume (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) was the recipient of unusually large options trading on Tuesday. Traders bought 31,566 put options on the stock. This is an increase of 1,329% compared to the average volume of 2,209 put options.

Aldeyra Therapeutics Trading Down 68.7%

Aldeyra Therapeutics stock traded down $2.91 during mid-day trading on Tuesday, hitting $1.33. The company had a trading volume of 42,245,261 shares, compared to its average volume of 1,824,579. Aldeyra Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.87. The company’s fifty day moving average is $4.98 and its 200-day moving average is $5.11. The company has a market capitalization of $79.74 million, a price-to-earnings ratio of -2.32 and a beta of 0.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts expect that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Aldeyra Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock worth $18,750,000 after acquiring an additional 90,276 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Aldeyra Therapeutics by 86.6% during the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after purchasing an additional 710,000 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Aldeyra Therapeutics by 275.4% in the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after purchasing an additional 1,081,257 shares during the period. Kennedy Capital Management LLC grew its position in shares of Aldeyra Therapeutics by 12.9% in the fourth quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock valued at $6,505,000 after purchasing an additional 143,625 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after purchasing an additional 8,769 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.